GSK's (GSK) "Underweight" Rating Reiterated at JPMorgan Chase & Co.

GSK (LON:GSK - Get Free Report)'s stock had its "underweight" rating reaffirmed by analysts at JPMorgan Chase & Co. in a research report issued on Friday, Marketbeat.com reports.

A number of other research analysts also recently issued reports on GSK. Shore Capital reaffirmed a "buy" rating on shares of GSK in a research report on Wednesday, April 30th. Deutsche Bank Aktiengesellschaft restated a "hold" rating and issued a GBX 1,450 ($19.45) price objective on shares of GSK in a research note on Tuesday, July 8th.

GSK Trading Down 0.3%

GSK traded down GBX 4 ($0.05) during trading on Friday, reaching GBX 1,344 ($18.03). 6,499,772 shares of the stock traded hands, compared to its average volume of 13,727,013. The stock has a market capitalization of £54.54 billion, a PE ratio of 21.71, a P/E/G ratio of 1.24 and a beta of 0.31. The stock's 50-day moving average is GBX 1,435.32 and its 200 day moving average is GBX 1,423.08. The company has a quick ratio of 0.73, a current ratio of 0.81 and a debt-to-equity ratio of 114.64. GSK has a 12 month low of GBX 1,242.50 ($16.67) and a 12 month high of GBX 1,678.68 ($22.52).

GSK (LON:GSK - Get Free Report) last issued its earnings results on Wednesday, April 30th. The company reported GBX 44.90 ($0.60) EPS for the quarter. GSK had a net margin of 8.02% and a return on equity of 18.08%. Equities analysts anticipate that GSK will post 175.980975 earnings per share for the current year.

Insiders Place Their Bets

In other GSK news, insider Emma Walmsley sold 5,473 shares of the stock in a transaction that occurred on Tuesday, May 6th. The stock was sold at an average price of GBX 1,449 ($19.44), for a total transaction of £79,303.77 ($106,376.62). Also, insider Jonathan Symonds bought 1,350 shares of the business's stock in a transaction that occurred on Friday, June 20th. The stock was purchased at an average price of GBX 1,435 ($19.25) per share, for a total transaction of £19,372.50 ($25,985.92). Over the last 90 days, insiders acquired 1,905 shares of company stock valued at $2,732,835. 1.61% of the stock is currently owned by corporate insiders.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.